FDA approves brigatinib

On April 28, 2017 the FDA granted Takeda (formerly Ariad) approval for Alunbrig (brigatinib) to be sold in the US to patients who are resistant to Crizotinib.

This entry was posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply